LLY and VKTX Related Headlines
Go Back- Oral GLP-1 obesity drugs see rapid early adoption, Bernstein survey shows
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
- Novo Nordisk (NVO) stock: Barclays breaks down key investor questions and debates
- Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX)
- Novo Nordisk, Eli Lilly rise after Viking obesity trial data
- JPMorgan on Viking Therapeutic (VKTX): 'we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile'
- Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
- Mizuho: Viking (VKTX) Oral Obesity Program is 'Quite Discouraging'
